A study conducted by researchers with The Ohio State University Wexner Medical Center, the National Registry of Emergency Medical Technicians
Continue reading »
Home » Medications »
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
MARLBOROUGH, Mass.–(BUSINESS WIRE) July 25, 2018 –Sunovion Pharmaceuticals Inc. (Sunovion) today announced that a study (SEP360-321 ) evaluating the efficacy
Continue reading »
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
DUBLIN, July 23, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food
Continue reading »
Pfizer says not part of failed Dutch pregnancy trial
Pfizer Thursday insisted its anti-impotency Viagra drug was not used in a Dutch study seeking to help pregnant women whose
Continue reading »
Chance of being prescribed opioids for minor injury differs dramatically by where you live
Patients who sought care for a sprained ankle in states that were found to be “high prescribers” of opioids were
Continue reading »
FDA Approves Symtuza
TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and
Continue reading »
Vickie Saves Over $850 a Year on Rosacea Treatment with GoodRx
Vickie, currently 60 years old, says she’s ineligible for Medicaid in her state, so she for as long as she’s
Continue reading »
BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
AIRPORT CITY, Israel, July 11, 2018 /PRNewswire/ — BioSight Ltd., a pharmaceutical development company focused on the development of targeted
Continue reading »
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of Pixuvri (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
SEATTLE, July 9, 2018 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ:CTIC) and Servier today announced that the pivotal Phase III trial
Continue reading »
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
SUMMIT, N.J. & CAMBRIDGE, Mass.–July 9, 2018 (BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today
Continue reading »